KR101578309B1 - 노치 경로 신호전달 억제제 화합물 - Google Patents

노치 경로 신호전달 억제제 화합물 Download PDF

Info

Publication number
KR101578309B1
KR101578309B1 KR1020147001731A KR20147001731A KR101578309B1 KR 101578309 B1 KR101578309 B1 KR 101578309B1 KR 1020147001731 A KR1020147001731 A KR 1020147001731A KR 20147001731 A KR20147001731 A KR 20147001731A KR 101578309 B1 KR101578309 B1 KR 101578309B1
Authority
KR
South Korea
Prior art keywords
cancer
compound
mmol
leukemia
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147001731A
Other languages
English (en)
Korean (ko)
Other versions
KR20140026624A (ko
Inventor
필립 아더 힙스킨드
그레고리 알란 스테펜슨
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20140026624A publication Critical patent/KR20140026624A/ko
Application granted granted Critical
Publication of KR101578309B1 publication Critical patent/KR101578309B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020147001731A 2011-07-27 2012-07-18 노치 경로 신호전달 억제제 화합물 Active KR101578309B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US61/512,016 2011-07-27
US201161560486P 2011-11-16 2011-11-16
US61/560,486 2011-11-16
PCT/US2012/047100 WO2013016081A1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Publications (2)

Publication Number Publication Date
KR20140026624A KR20140026624A (ko) 2014-03-05
KR101578309B1 true KR101578309B1 (ko) 2015-12-16

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147001731A Active KR101578309B1 (ko) 2011-07-27 2012-07-18 노치 경로 신호전달 억제제 화합물

Country Status (36)

Country Link
US (1) US8569286B2 (cg-RX-API-DMAC10.html)
EP (1) EP2736920B1 (cg-RX-API-DMAC10.html)
JP (1) JP6027110B2 (cg-RX-API-DMAC10.html)
KR (1) KR101578309B1 (cg-RX-API-DMAC10.html)
CN (1) CN103732612B (cg-RX-API-DMAC10.html)
AP (1) AP4080A (cg-RX-API-DMAC10.html)
AR (1) AR087107A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012287251B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014001600B1 (cg-RX-API-DMAC10.html)
CA (1) CA2841178C (cg-RX-API-DMAC10.html)
CL (1) CL2014000175A1 (cg-RX-API-DMAC10.html)
CO (1) CO6862159A2 (cg-RX-API-DMAC10.html)
CR (1) CR20140036A (cg-RX-API-DMAC10.html)
CY (1) CY1116645T1 (cg-RX-API-DMAC10.html)
DK (1) DK2736920T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2014000011A (cg-RX-API-DMAC10.html)
EA (1) EA023044B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP14013179A (cg-RX-API-DMAC10.html)
ES (1) ES2544937T3 (cg-RX-API-DMAC10.html)
GT (1) GT201400012A (cg-RX-API-DMAC10.html)
HR (1) HRP20150771T1 (cg-RX-API-DMAC10.html)
HU (1) HUE027534T2 (cg-RX-API-DMAC10.html)
IL (1) IL229988A (cg-RX-API-DMAC10.html)
JO (1) JO3148B1 (cg-RX-API-DMAC10.html)
MA (1) MA35611B1 (cg-RX-API-DMAC10.html)
ME (1) ME02171B (cg-RX-API-DMAC10.html)
MX (1) MX356536B (cg-RX-API-DMAC10.html)
MY (1) MY184303A (cg-RX-API-DMAC10.html)
PE (1) PE20141061A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014500215B1 (cg-RX-API-DMAC10.html)
PL (1) PL2736920T3 (cg-RX-API-DMAC10.html)
PT (1) PT2736920E (cg-RX-API-DMAC10.html)
RS (1) RS54135B1 (cg-RX-API-DMAC10.html)
SI (1) SI2736920T1 (cg-RX-API-DMAC10.html)
TW (1) TWI568730B (cg-RX-API-DMAC10.html)
WO (1) WO2013016081A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110506A2 (en) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US11564929B2 (en) 2016-04-12 2023-01-31 Eli Lilly And Company Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
MX380779B (es) * 2016-04-12 2025-03-12 Lilly Co Eli Terapia combinatoria con inhibidores notch y cdk4/6
EP3458091B1 (en) * 2016-05-20 2021-11-17 Eli Lilly and Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
JP2019526632A (ja) * 2016-08-31 2019-09-19 イーライ リリー アンド カンパニー 固形腫瘍の治療のための投薬レジメン
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
AU2018359907A1 (en) * 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
EP3790552A4 (en) * 2018-05-06 2022-06-15 Ayala Pharmaceuticals Inc. COMBINATION COMPOSITIONS WITH BISFLUORAKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THERE
BR112021006092A2 (pt) 2018-10-02 2021-07-20 Frequency Therapeutics, Inc. composições farmacêuticas que compreendem agentes terapêuticos óticos e métodos relacionados
MX2021012258A (es) 2019-04-08 2022-01-04 Frequency Therapeutics Inc Combinacion de chir99021 y acido valproico para tratar la perdida auditiva.
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711537B (en) * 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
AU4710199A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU4707999A (en) 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
CN100480248C (zh) 2003-02-04 2009-04-22 弗·哈夫曼-拉罗切有限公司 用作γ-分泌酶抑制剂的丙二酰胺衍生物
BRPI0413533A (pt) 2003-09-09 2006-10-10 Hoffmann La Roche derivados de malonamida que bloqueiam a atividade de gama-secretase
SI1673347T1 (sl) 2003-10-06 2015-10-30 F. Hoffmann - La Roche Ag Substituirani derivati dibenzo-azepina in benzo-diazepina, ki so uporabni kot inhibitorji gama-sekretaze
WO2007110335A1 (en) 2006-03-27 2007-10-04 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma secretase inhibitors
KR101150574B1 (ko) * 2007-02-02 2012-05-30 에프. 호프만-라 로슈 아게 6-옥소-6,7-다이하이드로-5h-다이벤조[b,d]아제핀-7-일 유도체
US20090181944A1 (en) 2008-01-11 2009-07-16 John Frederick Boylan Method for cancer therapy
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
CN103732612A (zh) 2014-04-16
ES2544937T3 (es) 2015-09-07
PE20141061A1 (es) 2014-09-06
BR112014001600B1 (pt) 2022-09-13
HRP20150771T1 (hr) 2015-08-28
DOP2014000011A (es) 2014-07-31
US20130029972A1 (en) 2013-01-31
CA2841178C (en) 2016-12-20
DK2736920T3 (en) 2015-07-20
EP2736920B1 (en) 2015-07-01
ME02171B (me) 2015-10-20
EA201490161A1 (ru) 2014-04-30
PT2736920E (pt) 2015-09-16
TWI568730B (zh) 2017-02-01
US8569286B2 (en) 2013-10-29
HUE027534T2 (en) 2016-11-28
JO3148B1 (ar) 2017-09-20
JP6027110B2 (ja) 2016-11-16
BR112014001600A2 (pt) 2017-02-21
JP2014527042A (ja) 2014-10-09
CR20140036A (es) 2014-03-21
CO6862159A2 (es) 2014-02-10
KR20140026624A (ko) 2014-03-05
PL2736920T3 (pl) 2015-11-30
PH12014500215A1 (en) 2014-03-17
EP2736920A1 (en) 2014-06-04
CA2841178A1 (en) 2013-01-31
EA023044B1 (ru) 2016-04-29
AP2014007362A0 (en) 2014-01-31
TW201315732A (zh) 2013-04-16
AR087107A1 (es) 2014-02-12
SI2736920T1 (sl) 2015-08-31
AP4080A (en) 2017-03-29
AU2012287251A1 (en) 2014-01-30
WO2013016081A1 (en) 2013-01-31
PH12014500215B1 (en) 2018-09-07
MY184303A (en) 2021-03-31
NZ618891A (en) 2015-12-24
CL2014000175A1 (es) 2014-08-22
ECSP14013179A (es) 2014-03-31
GT201400012A (es) 2014-07-16
MX356536B (es) 2018-06-01
CN103732612B (zh) 2015-09-23
MA35611B1 (fr) 2014-11-01
IL229988A (en) 2017-07-31
HK1194086A1 (en) 2014-10-10
RS54135B1 (sr) 2015-12-31
CY1116645T1 (el) 2017-03-15
AU2012287251B2 (en) 2015-05-14
MX2014001084A (es) 2014-02-27

Similar Documents

Publication Publication Date Title
JP6027110B2 (ja) ノッチ経路シグナリングインヒビター化合物
JP7462985B2 (ja) 芳香族化合物および抗腫瘍薬物の調製におけるその使用
AU2015370588B2 (en) Fused bicyclic compounds for the treatment of disease
WO2017161269A1 (en) Inhibitors of ret receptor tyrosine kinases
JP2017528503A (ja) 新規化合物αvβ6インテグリンアンタゴニスト
JP2021521243A (ja) Stat3阻害剤
CN115768757B (zh) Cd206调节剂及其用途和制备方法
CN113135929B (zh) 呋喃并吡啶酮酰胺化合物及其制备方法和用途
AU2014334619A1 (en) Alkyl linked quinolinyl modulators of RORyt
CN112778273B (zh) 环酮并吡啶酮类化合物及其制备方法和用途
EP4010343B1 (en) 7,8-dihydro-4h-pyrazolo[4,3-c]azepine-6-one compounds
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用
NZ618891B2 (en) Notch pathway signaling inhibitor compound
HK1194086B (en) Notch pathway signaling inhibitor compound
JP2016179959A (ja) 多環式リゾホスファチジルセリン誘導体

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20140122

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140122

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150323

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150917

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20151210

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20151210

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20181115

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20181115

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20201117

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20211118

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20241120

Start annual number: 10

End annual number: 10